BioInfect 2014 to Gather Life Science Professionals and Set the Global Antimicrobial Agenda
![](/46/pdcnewsitem/03/37/65/DpKR3UhMFQBU0fZ.jpg)
Bionow will be hosting the 2014 BioInfect Conference. A major one-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance, will take place at the Alderley Park Conference Centre, Cheshire on the 4 November 2014. The conference will again convene scientists, policy makers and government officials from across the world to drive forward and establish the global anti-microbial agenda.
The three main sessions that will be presented at the conference are “Progress: National and International Perspectives”, “Animal Health — the issues” and “Commercial Models.” In addition, there will be company technology showcases presenting leading innovation and development in this area. These include North West based Redx Anti-Infectives and Blueberry Therapeutics, QuantuMDx who are based in Newcastle and Discuva who are based in Cambridge.
Dr Geoff Davison, CEO of Bionow, commented: “To tackle growing levels of antimicrobial resistance, we need to address this global problem in a truly coordinated way to ensure that we have a health care system that can sustainably control and treat infections. BioInfect is a wonderful opportunity to bring together professionals from the life sciences industry, government and policy making bodies and explore the areas which can truly address this problem for mankind.”
BioInfect 2014 follows on from a very successful conference last year where Professor Dame Sally Davies, Chief Medical Officer, noted that "the golden age" of effective antibiotics has come to an end as no new class of drugs has been developing since 1987. She warned of the danger of going back to a pre-antibiotic era, where a simple infection could be a death sentence - a warning echoed by other speakers from around the globe. This year the Deputy Chief Medical Officer, Professor John Watson will inform delegates of the progress which the UK is making in the fight against this deadly threat.
BioInfect 2014, is hosted by Bionow and Redx Pharma, supported by AstraZeneca and sponsored by HGF Ltd, Boyd Consultants, Shore Capital and DWF LLP.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance